London-based GSK has introduced two cancer medicines Jemperli for certain advanced endometrial cancers and Zejula for advanced ovarian cancer, marking its formal entry into India’s oncology market. These cancers are increasingly common among Indian women, and many patients are diagnosed at later stages where treatment choices are limited. Endometrial and...